At a glance
- Originator Aventis
- Class Antiplatelets
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 14 Aug 2001 Discontinued-Clinical for Thrombosis in Germany (PO)
- 29 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 09 Jun 1999 Investigation in Thrombosis in Germany (PO)